Evidence mapPaperPMID 39170992Full record

ReviewCureus2024

Inflammatory Bowel Disease and Cardiovascular Disease: An Integrative Review With a Focus on the Gut Microbiome.

Camila Sanchez Cruz, Anahi Rojas Huerta, Jesus Lima Barrientos, Cristina Rodriguez, Aarfa Devani, Vanessa Boosahda, Naga S Rasagna Mareddy, Gabriela Briceno Silva, Jose C Del Castillo Miranda, Kevin A Reyes Gochi and 3 more

Abstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. mSphere · 2025
    Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Camila Sanchez CruzGeneral Practice, Universidad Nacional Autonoma de Mexico, Mexico City, MEX.
Anahi Rojas HuertaGeneral Practice, Benemérita Universidad Autónoma de Puebla, Puebla, MEX.
Jesus Lima BarrientosGeneral Practice, Benemérita Universidad Autónoma de Puebla, Puebla, MEX.
Cristina RodriguezInternal Medicine, RWJBarnabas Health Community Medical Center, Toms River, USA.
Aarfa DevaniGeneral Practice, Malla Reddy Institute of Medical Sciences, Hyderabad, IND.
Vanessa BoosahdaGeneral Practice, Xavier University School of Medicine, Oranjestad, ABW.
Naga S Rasagna MareddyRadiology, University of Alabama at Birmingham, Birmingham, USA.
Gabriela Briceno SilvaObstetrics and Gynaecology, Universidad de Oriente, Barcelona, VEN.
Jose C Del Castillo MirandaGeneral Practice, Universidad Peruana Cayetano Heredia, San Martín de Porres, PER.
Kevin A Reyes GochiSchool of Medicine, Universidad Nacional Autonoma de Mexico, Mexico City, MEX.
Mario D Reyes GochiSurgery, Universidad Nacional Autonoma de Mexico, Mexico City, MEX.
Samantha AlvarezGeneral Practice, St. George's University, West Indies, GRD.
Patricia E Ghattas HasbunGeneral Practice, Universidad Católica de Honduras, Tegucigalpa, HND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is a chronic inflammatory condition of the gastrointestinal tract. Recent research indicates a significant link between IBD and cardiovascular disease (CVD), the leading cause of global morbidity and mortality. This review examines the association between IBD and CVD, emphasizing the role of the gut microbiome in this relationship. IBD patients have a higher risk of cardiovascular events, such as coronary artery disease, heart failure, and cerebrovascular incidents, primarily due to chronic systemic inflammation, genetic factors, and gut microbiota imbalance (dysbiosis). Dysbiosis in IBD increases intestinal permeability, allowing bacterial products to enter the bloodstream, which promotes inflammation and endothelial dysfunction, contributing to CVD. Understanding the gut microbiome's role in IBD and CVD suggests new therapeutic interventions. Modulating the microbiome through diet, probiotics, and fecal microbiota transplantation (FMT) are promising research avenues. These interventions aim to restore a healthy gut microbiota balance, potentially reducing inflammation and improving cardiovascular outcomes. Additionally, the review emphasizes the importance of regular cardiovascular risk assessments and personalized preventive measures in managing IBD patients. Such measures include routine monitoring of cardiovascular health, tailored lifestyle modifications, and early intervention strategies to mitigate cardiovascular risk. By integrating current knowledge, this review aims to improve understanding and management of the interconnected pathophysiology of IBD and CVD. This approach will ultimately enhance patient outcomes and provide a foundation for future research and clinical practice guidelines in this area.

Indexed as

cardiovascular disease (cvd)chronic systemic inflammationdysbiosis and endothelial dysfunctiongut microbiomeinflammatory bowel disease (ibd)

Identifiers

PMID39170992
PMCPMC11338650

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.